BCL3
BCL3 (B-cell lymphoma 3 protein) is an ankyrin repeat-containing transcriptional coactivator that contributes to the regulation of NF-kappa-B target genes and cell proliferation. It was previously known as B cell CLL/lymphoma 3 and carries the aliases D19S37 and BCL4. Browse Assay Genie's current range of BCL3 research reagents below, or read on for the biology behind the target.
BCL3 contributes to the regulation of transcriptional activation of NF-kappa-B target genes, and its activity depends on where it sits in the cell. In the cytoplasm, it inhibits nuclear translocation of the NF-kappa-B p50 subunit. In the nucleus, it acts as a transcriptional activator that promotes transcription of NF-kappa-B target genes. It also contributes to the regulation of cell proliferation.
The BCL3 protein contains seven ankyrin repeats, which are most closely related to those found in I kappa B proteins, and HGNC places the gene in the NFKB inhibitor family and the wider ankyrin repeat domain containing group. It functions as a transcriptional co-activator through its association with NF-kappa-B homodimers. UniProt records the protein in the nucleus, the cytoplasm and the perinuclear region of the cytoplasm. The mouse ortholog is Bcl3.
The BCL3 gene is regarded as a proto-oncogene candidate. It was identified through its translocation into the immunoglobulin alpha-locus in some cases of B-cell leukaemia, which gave rise to the B cell CLL/lymphoma 3 name. Its expression can be induced by NF-kappa-B, forming part of an autoregulatory loop that controls the nuclear residence of p50 NF-kappa-B. HGNC also lists the locus among the microRNA protein coding host genes.
BCL3 modulates NF-kappa-B target gene transcription and the nuclear residence of p50, making it a focus for studying how this pathway is regulated.
As a coactivator acting through NF-kappa-B homodimers, BCL3 is used to examine how ankyrin repeat proteins shape gene expression.
BCL3 was identified through a translocation into the immunoglobulin alpha-locus in some B-cell leukaemias, and it remains a proto-oncogene candidate.
BCL3 contributes to the regulation of cell proliferation, so it is studied in work on growth control downstream of NF-kappa-B.
BCL3 contributes to the regulation of NF-kappa-B target gene transcription. In the cytoplasm it inhibits nuclear translocation of the p50 subunit, while in the nucleus it acts as a transcriptional activator of NF-kappa-B target genes. It also contributes to the regulation of cell proliferation.
The HGNC-approved name is BCL3 transcription coactivator, and UniProt lists B-cell lymphoma 3 protein. Previous names include B cell CLL/lymphoma 3, and the gene has also been known by the symbols D19S37 and BCL4.
BCL3 is a proto-oncogene candidate, identified by its translocation into the immunoglobulin alpha-locus in some cases of B-cell leukaemia. A mouse ortholog, Bcl3, exists. Check the datasheet of any product for its validated reactivity.
Other BCL-family proteins, transcriptional regulators and lymphoma-associated targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P20749; product specifications from Assay Genie datasheets.